FindMyKOL

Yelena Novik, MD

Basic profile

NYU Langone Health

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionNew York, NY · NortheastSpecialtyHematology / OncologyFocusOncology
Last active 2024FindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2006–2012Why? →

Yelena Novik is an Oncology physician affiliated with NYU Langone Health. OpenAlex indexes 84 publications with 1,578 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
84publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

1,578citations

Citations across these publications.

16h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2006–2012

Federally funded research awards.

View funding ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Novartis
    Program year20252 paymentsResearch
    $22,889
  • Astellas
    Program year202536 paymentsResearch
    $20,575
  • Pfizer
    Program year20252 paymentsResearch
    $20,000
All 32 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Aromatase Inhibitor100%
    Letrozole60%Anastrozole26%Exemestane14%
    Part D≥89 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 2006–2012 per NIH RePORTER. The latest:

All 8 award records: search, sort and filter.Explore →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”